See the latest news and media coverage for Insmed. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing therapies for serious diseases
insmed.comLast updated
In short: Insmed secured global regulatory approvals for BRINSUPRI, reported record 2026 revenues, and advanced its respiratory clinical pipeline.
The once-daily oral medication targets non-cystic fibrosis bronchiectasis, marking the first MHLW-approved treatment for this progressive condition in adults and pediatric patients aged 12 and older.
The company presents key highlights from the quarter, with the full report available.
Total revenues reached $425.5 million; BRINSUPRI brought in $309.2 million. Insmed raised BRINSUPRI's 2026 guidance to $1.25-$1.40 billion and peak revenue estimates to over $14 billion.
Sustained improvement in 6MWD, NT-proBNP, WHO class, and REVEAL Lite 2.0; placebo crossed group showed similar benefits.
INSM fell 4.63% to $119.50 from $125.30 the previous trading day Weiss Ratings assigns D- (Sell) Market cap is $27.36B Insmed ...
Insmed's revenues in the second quarter increased significantly, driven by BRINSUPRI with $309.2 million and ARIKAYCE with $116.3 million, which moved the shares pre-market...
Insmed shares rose 3.71% today to $129.39: an upgraded sales forecast for BRINSUPRI boosts investor optimism and trading momentum.
On August 6, Insmed (NASDAQ:INSM) reported second-quarter results that mark a turning point for a company long defined by red ink. Total revenue hit $425.5...
Track Insmed and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Insmed and other trending companies.